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Single nucleotide polymorphismThe success of genome-wide association studies has paralleled the development of efﬁcient genotyping
technologies. We describe the development of a next-generation microarray based on the new highly-
efﬁcient Affymetrix Axiom genotyping technology that we are using to genotype individuals of European
ancestry from the Kaiser Permanente Research Program on Genes, Environment and Health (RPGEH). The
array contains 674,517 SNPs, and provides excellent genome-wide as well as gene-based and candidate-SNP
coverage. Coverage was calculated using an approach based on imputation and cross validation. Preliminary
results for the ﬁrst 80,301 saliva-derived DNA samples from the RPGEH demonstrate very high quality
genotypes, with sample success rates above 94% and over 98% of successful samples having SNP call rates
exceeding 98%. At steady state, we have produced 462million genotypes per week for each Axiom system. The
new array provides a valuable addition to the repertoire of tools for large scale genome-wide association
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The past decade has witnessed a revolution in genomics technol-
ogy, enabling the correlation of common genetic variation with a
variety of human traits anddiseases through genome-wide association
studies (GWAS) [1–4]. The large majority of these associations are not
detectable by conventional linkage analysis, which is well powered
primarily forMendelian diseases and/or genes with high relative risks.
While there has been recent debate regarding the success and
signiﬁcance of GWA studies [5,6], it is unequivocal that these studies
have produced a large number of clearly replicated novel genetic
associations with many diseases for which there had previously been
no speciﬁc genes identiﬁed. It is also clear that the tools used to date
have been based primarily on common genetic variation (minor allele
frequency (MAF) of 0.10 or greater), leaving the door open for the
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Fig. 1. Results of QC analysis on the Kaiser Permanente RPGEH GERA cohort using the Affymetrix Axiom system. (a) Cumulative distribution of DQC scores for 80,301 genotyped
saliva samples. (b) Sample call rate versus DQC derived from 76,412 genotyped saliva samples. Only samples passing a DQC threshold of 0.82 are included. Red line indicates
threshold for passing call rate. (c) Cumulative distribution of sample call rates for 76,412 genotyped samples. Only samples passing a DQC threshold of 0.82 are included.
(d) Cumulative distributions for call-nocalls and miscalls based on 818 duplicate samples.
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ants that are less common, provided that the necessary tools and
sample sizes can be developed. This has also recently been made0.0 0.2 0.4
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Fig. 3. Genome-wide coverage for the new array for a target set of Affymetrix validated CEU SNPs using either Affymetrix genotypes (dashed lines) or the 1000 Genomes Low Pass
(KGLP) genotypes (solid lines). Coverage based on imputation with “leave-one-out cross validation.” The numbers in parentheses in the legend are the numbers of markers in the
target set in each particular minor allele frequency range.
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Fig. 4. Genome-wide coverage for the new array (solid lines) versus the Affymetrix 6.0 array (dashed lines) for a target set of 1000 Genome High Pass (KGHP) SNPs using 1000
Genomes Low Pass (KGLP) genotypes. Coverage based on imputation with “leave-one-out cross validation.” The numbers in parentheses in the legend are the numbers of markers in
the target set in each particular minor allele frequency range.
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Fig. 5. Genome-wide coverage of the new array for two complementary target sets: KGHP SNPs with Affymetrix validated SNPs removed (solid lines), and KGLP SNPs with KGHP and
Affymetrix validated SNPs removed (dashed lines). Coverage based on imputation with “leave-one-out cross validation” using KGLP genotypes. The numbers in parentheses are the
numbers of markers in the two target sets in each particular minor allele frequency range.
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Fig. 6. Coverage of the new array (solid lines) versus the Affymetrix 6.0 array (dashed lines) for a target set of Canary CNVs using Canary CNV and Affymetrix genotype data. Coverage
based on imputation with “leave-one-out cross validation.” The numbers in parentheses are the numbers of CNVs in the target set in each particular minor allele frequency range.
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83T.J. Hoffmann et al. / Genomics 98 (2011) 79–89The success of GWAS has been driven by the emergence and
evolution of reliable and high-throughput genotyping platforms
capable of simultaneously assaying hundreds of thousands of SNPs.
Of the various genotyping technologies currently available, Affymetrix
Axiom™ array plates and GeneChips™ and Illumina's Inﬁnium
BeadChips™ offer the highest SNP density and are mostly commonly
used for GWAS [9].
The content of these high-density SNP arrays generally comes from
the work of large SNP discovery consortia, including The SNP
Consortium (TSC), followed by the International HapMap Project,
and most recently the 1000 Genomes Project (KGP). As the SNP
catalogs produced by the consortia grew, an early question was the
extent of linkage disequilibrium (LD) among common variants in the
human population and the degree to which untyped variants
associated with disease could be detected through LD with genotyped
SNPs [10,11]. As dense genetic maps emerged it became evident that
the human genome is comprised of regions with extended LD and
limited haplotype diversity, depending on the particular population
studied. Within such regions the genotypes of common SNPs could be
inferred from the genotypes of a smaller number of “tag” SNPs [12].
This meant that commercial chip designs assaying approximately
500,000 SNPs could potentially capture the majority of common
genetic variation in most human populations. It was also recognized
that African-derived populations have greater genetic diversity and
lower levels of LD, requiring a greater density of SNPs to provide
genome-wide coverage of common variation. With advances in
technology for massively parallel genotyping of SNPs, the capacity
of commercial arrays evolved to deliver very high density SNP
capabilities, thus enabling highly powered GWAS [13].
Until recently the International HapMap project (http://www.
hapmap.org) has been the primary data source for commercial SNP
panels. The objective of the HapMap project when initiated in 2002
was to genotype common (MAFN0.05) SNPs across the genomes of
270 individuals from European, African, and Asian populations.
Genotypes for more than 3 million SNPs were released by the
Consortium by 2007, as well as the characterization of local LD
patterns across the human genome. These Phase I and Phase II
HapMaps guided SNP selection strategies for commercial SNP panels
to “capture” the common variation in these particular populations.
The progression of Affymetrix arrays for massively parallel
genotyping of SNPs (Table 1) illustrates the general progress of the
ﬁeld, beginning with the Mapping 10 K array [14]. The technology for
the ﬁrst array overcame two bottlenecks: the requirement for locus-
speciﬁc SNP ampliﬁcation and locus-speciﬁc allele discrimination. The
source of variants was the TSC project and SNPs discovered by
Perlegen Science's resequencing project, and criteria for selecting
SNPs for the array resulted in a bias towards those with high (N0.1)
MAF. The Mapping 100 K array set [15] was the ﬁrst in a family of
products suitable for association studies, and in fact produced the ﬁrst
GWAS ﬁnding, for adult onset macular degeneration and complement
factor H [16]. The SNP selection process required at least two minor
alleles in the 108 chromosomes genotyped, and consequently 90% of
the SNPs are common.
The Mapping 500 K array (http://media.affymetrix.com/support/
technical/datasheets/500k_datasheet.pdf) was the ﬁrst array set withTable 1
Historical progression of Affymetrix SNP genotyping arrays. The number of SNPs/array has
during this time period. These advances were the result of innovations in array feature size,
area and overall productivity.
Year 2003 2004 2005
Product Mapping 10 K Mapping 100 K Mapping
# SNPs 10,000 100,000 500,000
# SNPs/mm2 60 300 1,500
# Samples/week Not deﬁned Not deﬁned N96sufﬁcient density to enable highly powered GWAS. SNPs were
selected to be polymorphic in the HapMap populations, and average
heterozygosity in those populations was 0.29. The Affymetrix SNP 5.0
array has essentially the same SNP content as the Mapping 500 K, but
the design involves multiple replicates of the most informative probes
rather than a single copy of many different probe sequences [17],
leading to reduced cost and increased throughput. Affymetrix SNP 6.0
was the next generation array. The design was based on screening
more than two million additional SNPs (chosen from HapMap and
dbSNP) and selecting 906 K SNPs to optimize coverage of common
HapMap Phase II variants in Europeans, East Asians andWest Africans.
As we show later, the SNP 6.0 array provides excellent whole genome
coverage for genetic variants with MAF greater than 0.1.
The Axiom™ Genotyping Solution (http://media.affymetrix.com/
support/technical/datasheets/axiom_genotyping_solution_datasheet.
pdf) is the newest genotyping product developed to increase the
power of a study by substantially increasing sample throughput with
arrays that maximize genetic coverage for at least one population.
Here we describe a newly developed Axiom array intended to provide
coverage of both common and lower frequency variation in the
European population; similar arrays for other ethnic groups are also
under development.
The Axiom genotyping platform is a two color, ligation-based assay
utilizing 30-mer oligonucleotide probes synthesized in situ on a
microarray substrate, with automated, parallel processing of 96
samples per plate. Features are 3 μm squares, at a pitch of 5 μm
center-to-center, with a total of ~1.38 million features available for
experimental content. Each SNP feature contains a unique oligonu-
cleotide sequence complementary to the genomic sequence ﬂanking
the SNP site on either the forward or reverse strand. Solution probes
bearing attachment sites for one of two dyes, depending on the 3'
(SNP-site) base (A or T, versus C or G) hybridize to the glass probe/
target complex, and are then ligated for speciﬁcity. Features are
typically replicated twice on the array, so that each SNP is
interrogated by two features; A/T and C/G SNPs require four features,
because the two alleles match the same dye and therefore distinct
probe sequences in different physical locations on the array are
required to distinguish them. A maximum of ~690,000 SNPs may be
accommodated by this format; this number is reduced if A/T or C/G
SNPs are included, or if additional features are used to improve the
resolution of speciﬁc SNPs, but may also be increased if high
resolution SNPs are tiled with a single feature. The platform can be
leveraged for designing arrays at previously unattainable levels of SNP
density with respect to customization of variant selection.
Here we describe the development and quality characteristics of a
new microarray for the Axiom system tailored to the European
population. This is the ﬁrst in a series of custom arrays being developed
for a genome-widegenotyping analysis of 100,000participants fromthe
Kaiser Permanente Northern California Research Program on Genes,
Environment and Health. The rationale for developing these new arrays
is to maximize the number of high quality SNPs for genome-wide
coverage; to provide coverage down to a minor allele frequency of 0.01
in gene-based regions; to saturate regions previously identiﬁed as
disease associated from prior GWA studies for both replication and ﬁne
mapping; to improve coverage of both common and uncommonincreased ~100x in ﬁve years. Signiﬁcant increases in throughput have also occurred
assay, hardware and genotyping algorithms resulting in increased SNP density per unit
2006 2007 2009
500 K SNP 5.0 SNP 6.0 Axiom Genotyping Solution
500,000 900,000 up to 690,000
3,000 6,000 19000
N96 N96 N750
84 T.J. Hoffmann et al. / Genomics 98 (2011) 79–89variants bymakinguse of data from the lowpass andhigh pass phases of
the 1000 Genomes Project; and to incorporate redundant coverage of
SNPs with known strong associations with disease or trait outcomes.
2. Results
2.1. Array statistics
Because the described Axiom array was developed as part of the
Kaiser Permanente-UCSF collaborative RC2 project speciﬁc for
European ancestry populations, it has been given the designation
AxiomGenome-Wide EUR Array Plate. In total, there are 674,517 SNPs
tiled onto the microarray. Among these, 116 are mitochondrial, 289
are on the Y chromosome, 388 are pseudoautosomal, 12,735 are on
the X chromosome, and the remaining 660,989 SNPs are autosomal.
Even though it is optimized for individuals of European ancestry,
because of close kinship we expect it to also have high utility for
individuals of West Asian, North African and South Asian ancestry.
2.2. Performance on HapMap samples
Performance of the array was assessed by assaying the Caucasian
and Yoruban HapMap2 populations (90 individuals each with cell line
DNA). Results are shown in Table 2. Call rates, sample concordance,
reproducibility and Mendelian consistency are all extremely high.
Furthermore, a largemajority of SNPs (98.5%) have overall call rates of
97% or greater.
2.3. Performance on the KP RPGEH GERA cohort
To date, we have completed genotyping of 80,301 saliva samples
over a 9 month period, using 3 Affymetrix Gene Titan systems and 3
Beckman Biomek FXP Target Prep Express Systems, including 818
pairs of duplicate samples. That translates to approximately 685
samples per week per system, and 462 million genotypes per week
per system. We used the Affymetrix Powertools Package version
1.12.0 [18] to make the genotype calls.
Fig. 1a is the cumulative distribution of DQC (quality control),
scores for the 80,301 samples. Among these, 76,508 (95.3%) had
passing DQC scores (N0.82). Fig. 1b is a scatter plot showing the
distribution of sample call rate vs. DQC for samples with DQCN0.82.
We see a strong correlation between the two measures, and that the
great majority of the samples fall along a “main sequence” of behavior.
Below themain sequence is a diffuse halo of samples whose call rate is
below expected. Although few in number, these samples below the
call rate threshold of 97% show the necessity for a second ﬁltering and
genotyping step in the standard workﬂow.
Fig. 1c shows the cumulative distribution of sample call rates for
sample assays with DQCN0.82. Among the 76,508 samples with
DQCN0.82, 75,740 (99.0%) have a “passing” call rate of 97% or greater.
Overall, 87% of the samples have a call rate ≥99% and over 98% of
samples have a call rate ≥98%. From the original group of 80,301
samples, 94.3% pass both DQC and call rate criteria.
Genotype reproducibility was assessed from the 818 duplicate
samples. There are two types of disagreement between duplicate
samples. The ﬁrst we refer to as a “call–no call” (CNC) — where oneTable 2
Performance of the array on 180 HapMap 2 individuals.
Metric Performance
Average Sample Call Rate 99.69%
Average Sample Concordance to HapMap Reference Genotypes 99.71%
Fraction of SNPs with Call RateN97% 98.5%
Average SNP Reproducibility 99.89%
Mendelian Inheritance Accuracy 99.94%sample has a genotype call, while the other is considered a no call. The
second we refer to as a “miscall.” This occurs when both samples
receive genotype calls, but the calls differ. We calculated both the CNC
rate (total number of disagreements out of total number of SNPs) and
the miscall rate (total number of miscalls out of total number of SNPs)
for each pair of duplicate samples. The majority of samples had CNC
rates below 1%, with 0.7% of samples having a rate of 3% or higher and
4.8% with rates between 2% and 3% (Fig. 1d). Similarly, the majority of
samples had miscall rates below 0.5%, with 1% having a miscall rate
greater than 2% (Fig. 1d).
There was also a strong correlation between CNC and miscall rates
for the duplicate samples (r=0.93), indicating that samples with
lower DQC and overall call rates are also likely to have a higher rate of
miscalls. These miscall rates are conservative overestimates because
they are based on ﬁrst pass genotyping, and presumably can be
brought down further based on more reﬁned genotyping procedures
and higher stringency for genotype calls. We also noted that for
miscalls, the large majority (97.6%) occurred between homozygotes
and heterozygotes, and rarely between the two different homozy-
gotes. This is consistent with occasional difﬁculties in clearly assigning
a genotype to a given sample when adjacent clusters may not be very
well separated.
2.4. Genome-wide coverage
We ﬁrst compared the coverage of our array to the Affymetrix 6.0
chip, which includes over 906,600 SNPs [17]. Because coverage is
dependent on MAF, we stratiﬁed all coverage ﬁgures based on MAF.
We ﬁrst looked at the coverage of the “target set” that the array was
designed for (3,431,598 SNPs with MAF≥0.02), stratiﬁed by MAF
ranges. We see in Fig. 2 that that the new array provides coverage
comparable to Affymetrix 6.0 for common SNPs (MAF≥0.1), but has
higher coverage for lower allele frequencies, down to 0.03 frequency,
despite having fewer SNPs on the microarray. This is because the
Affymetrix 6.0 chip was designed from a smaller target set and was
not an ethnic-speciﬁc chip. It is signiﬁcant that coverage is still good
down to 0.03 MAF, where greater than 60% of SNPs are covered with
an r2 of 0.8.
We know that this target set is incomplete (e.g., not all the KGP
data were screened at design time). A larger set of 6,367,892 SNPs
with MAF≥0.02 have been identiﬁed in the sequencing of 60 CEU
individuals in the low pass sequencing phase (KGLP) of the KGP
(http://www.1000genomes.org). This pilot dataset was sequenced at
low (2–4X) coverage [19–22]. Some of the genotype calls for these 60
subjects available on the KGP website had been improved through
imputation with HapMap 3 data [23]. Because of potential noise from
the low pass sequencing, it was unclear whether the KGLP dataset
could provide an accurate estimate of genome-wide coverage, so we
ﬁrst looked at coverage for the set of SNPs overlapping those in the
target set for which the array was designed (Affymetrix data) and
KGLP.
In Fig. 3 we see that the coverage calculated using these two sets of
genotype data for the same target SNPs was very similar. Hence, we
conclude that the KGLP genotype data serve as an adequate reference
set for subsequent analyses.
We were next concerned with estimating genome-wide coverage
based on a random collection of valid SNPs, not limited to the SNPs
used for the array design, to obtain an unbiased estimate of full
genome coverage. To do so, in theory, we could focus simply on the
totality of KGLP SNPs. However, because the KGLP SNP data were
obtained from low pass sequencing, we were concerned about the
possible role of false positives in these data. These will likely be
particularly common for putative SNPs with low MAF. On the other
hand, we know that the KGP Pilot high pass sequencing data (KGHP)
were created with a much higher read depth (20–60x), although
sequencing was only performed on 4 independent individuals (two
85T.J. Hoffmann et al. / Genomics 98 (2011) 79–89CEU parents and two YRI parents). Sequence variations derived from
these 4 founders can be considered a random sample of genotypes,
albeit biased towards common variants due to the small number of
individuals examined. Although lowMAF SNPs are under-represented
in this group overall, they still occur in this sample and represent a
random sampling of low frequency variants. Therefore, to get another
estimate of genome-wide coverage for a random set of valid SNPs,
including common as well as rare alleles, we calculated coverage for
KGHP-derived SNPs that also appeared in the KGLP data, and used the
KGLP genotype data to determine coverage. We see that our array has
good coverage when using all markers in KGHP as the target set
(Fig. 4), although not as strong as for the Affymetrix target set for
which it was designed (Fig. 2). For the original Affymetrix coverage
set, at an r2 of 0.6, coverage ranged from about 74% at MAF of 0.03 to
96% at MAF of 0.1 or greater, while for the KPHP target set, coverage
ranged from about 60% at MAF of 0.03 to 94% at MAF of 0.2. However,
we also note that these coverage estimates are likely to be
conservative, as they are based on a relatively small sample of 60
KGLP individuals. Therefore, the coverage of SNPs with MAF of 0.03 is
likely to be higher than 60% for a larger reference panel.
We were also interested in comparing coverage of those SNPs that
appeared in the KGLP data but did not appear in the KGHP or the
Affymetrix database compared with those that did appear in the
KGHP data (but not the Affymetrix database). For SNPs missing from
KGHP, coverage was signiﬁcantly worse (Fig. 5), in comparison to
those that did appear in KGHP. This indicates that many of these KGLP
SNPs are likely false positives, leading to absence of LD with
neighboring SNPs and therefore a lack of coverage. Hence, caution
needs to be exercised in terms of genome-wide SNP coverage
estimates based solely on KGLP data.
Lastly, we looked at the coverage of the CNV data detectable on the
Affymetrix 6.0 chip [17,24,25] by our newly designed EUR array
(Fig. 6). The dataset used for this analysis was based on 59
independent CEU HapMap individuals; because CNVs were not
included in the EUR chip design and the SNP 6.0 chip uses a very
different assay compared to Axiom (hybridization-based instead of
ligation-based), this analysis also provides an independent estimate of
how well the chip can cover variants not included in the target set
used in the chip design. For this analysis we discarded 216 “multi-
allelic” CNVs (i.e., CNVs that could not be treated as SNPs, e.g., a CNV
that could have 0, 1, 2, or 3 copies) and 632 “bi-allelic” CNVs (i.e., can
be treated as a bi-alellic SNP) with MAFb0.02, and report coverage of
293 “bi-allelic” CNVs with MAF≥0.02. We would anticipate CNV
coverage to be comparable to the random SNP coverage as depicted in
Fig. 4. Such is the case down to a MAF of 0.1. However, below that
point, CNV coverage is reduced compared to SNPs. As yet, we are
uncertain as to the cause of this decrease; possibilities include
reduced accuracy of the CNV calling for low frequency CNVs, and
heterogeneous origins of lower frequency CNVs, both of which would
reduce neighboring linkage disequilibrium and hence imputation
ability. Again, these coverage estimates are likely to be conservative
because of the small size of the reference data set of genotypes for this
analysis.
3. Discussion
While genotyping chips with up to 1 million SNPs have now been
extensively applied in numerous GWA studies, questions about
coverage of low frequency variation remain. Also, throughput and
expense have previously been limitations for large scale application of
high density genotyping chips.
The current Axiom system and the associated genotyping arrays, as
describedhere for the Europeanpopulation, offer a newopportunity to
rectify some of these previous limitations. We have shown the array
described here, with approximately 675,000 SNPs, offers a new
solution to high throughput, reduced cost genotyping that alsoprovides coverage of low frequency variation. This development was
required due to the large scale genotyping necessary for the KP RPGEH.
In considering the genotyping platform for the project to obtain
genome-wide SNP data for 100,000 individuals of diverse ethnicity in
14 months, we chose the Axiom/GeneTitan platform over the
Affymetrix HuSNP 6.0 and the Illumina Omni1-Quad Inﬁnium HD
platforms available in September 2009 because of 4 main reasons.
First, the Axiom system allowed us to design custom SNP panels with
great ﬂexibility. Once the SNP panel is designed, fully manufactured
Axiom arrays are shipped in less than 6 weeks. Second, the Axiom
assay protocol is highly automated using microtiter plates with
substantially less hands on time than that required on the other two
platforms. The tasks performed by technicians involve simple
manipulations of microtiter plates placed onto robotic equipment
and reagents into reservoirs. In contrast, the Inﬁnium and Affy 6.0
protocols require handling of glass slides and DNA chips that require
more sophisticated skill and mental concentration. Technician burn-
out was a serious concern when considering the size of our project.
Third, the GeneTitan is a compact system that has a small footprint.
The amount of space required to house the iScans and robotic
workstations needed for the Inﬁnium platform is about 3 times that
required for the Axiom platform. Fourth, sample tracking is robust in a
96-array format of the Axiom system. With the samples arrayed
randomly according to gender, checking for male/female mismatches
in the genotyping data is a simple way to conﬁrm that there are no
sampling errors.
To date, we have completed genotyping of approximately 80,000
RPGEH samples in a 9 month period, using three Axiom Gene Titan
systems and three Beckman FXP Target Prep Express Systems. This
translates to approximately 685 samples and 462 million genotypes
per week per Gene-Titan system. The high throughput of this system
will enable us to complete the successful genotyping of 100,000
RPGEH subjects in a period of 14 months or less.
As expected, the array demonstrates excellent coverage down to a
MAF of 0.03 for the millions of SNPs it was designed to cover; but we
have also shown excellent coverage for other random SNPs down to a
MAF of 0.05 and reasonable coverage to even lower MAF of 0.03.
Special attention was paid in the design process to coverage of SNPs
with known or plausible disease associations, with the result that the
chip provides very good coverage of SNPs with potential biological
importance, such as SNPs in the regions of ADME genes, MHC genes,
or genes associated with cardiovascular disease or cancer [26].
We believe that the next generation of genotyping chips, for
example the Axiom based chip described here, will provide novel
associations with both low frequency and common variants, espe-
cially on large scale, well phenotyped studies. The ﬁrst 100,000
samples from the Kaiser Permanente Research Program on Genes,
Environment and Health to be genotyped, as described here, is but
one such example. From its design, the custom chip will also facilitate
replication and extension studies of previously identiﬁed associations,
and because of its focus on SNPs of pharmacogenetic interest, will also
be a valuable tool for studying genetic effects on treatment response
and side effects.
The high throughput and reduced cost with the Axiom system are
attained at a tradeoff with ethnic-speciﬁc coverage. Lower frequency
variants, for example those with frequency below 0.1, have an
enhanced probability of being race/ethnic group speciﬁc. Thus, in a
multi-ethnic study, different custom chips are required. We are
currently designing other arrays speciﬁc for East Asians, African
Americans and Latinos, which will be described in a subsequent
publication.While we expect a large amount of overlap in SNP content
on these different arrays for common variants (i.e., those with
MAFN0.1), we also anticipate inclusion of a sizable number of SNPs
that are unique to that ethnic group at a MAF of 0.02 or greater.
It is likely that genome-wide genotyping chips will continue to be
more efﬁcient and less expensive to apply than whole genome
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populations, the importance of diverse ethnic groups will lead to next
generation arrays that provide signiﬁcantly improved coverage of
more relevant variants. The development of new platforms and arrays
as described here will offer enhanced and complementary tools for
genome-wide analysis to identify the genetic basis of complex
diseases and traits, as has already been demonstrated for the earlier
generation genotyping tools.
4. Materials and methods
4.1. SNP validation (conversion)
SNPs screened using the Axiom™ technology were validated
(“converted”) according to several metrics encompassing the follow-
ing general principals:
4.1.1. Resolution
Cluster resolution was assessed by cluster separation and call rate.
The Axiom GT1 algorithm adapts pre-positioned clusters to the data
using a probability-based method. Clustering is carried out in two
dimensions, log ratio (log2(A)− log2(B)) and size (log2(A+B)/2). The
algorithm is very similar to the modiﬁed version of BRLMM-P
described in [24], except that no manual adjustment of priors was
performed, only bi-allelic SNPs and indels are considered, and
posterior estimation is dynamic using multiple samples in combina-
tion with predetermined priors. Cluster separation or resolution was
measured by the minimum pairwise Fisher's Linear Discriminant
(FLD) [27] between either homozygous cluster and the heterozygote
cluster, in the log ratio dimension. A minimum threshold of 3.6 has
been empirically determined to eliminate the great majority of poorly
resolved SNPs. SNP call rate was also calculated, with a minimum
threshold for conversion of 98% in the screen of KGP SNPs discussed
below. Additional measures of relative cluster position are used to
eliminate a variety of rare mis-clustering phenotypes that are not
caught by the FLD and call rate thresholds.
4.1.2. Polymorphism
A minimum of three observed examples of the minor allele (e.g.,
three heterozygotes, or one heterozygote and one minor allele
homozygote) was required for validation of a SNP. This provided
evidence for both proper assay function and resolution and the
existence of an actual polymorphism at the indicated site.
4.1.3. Accuracy
Accuracy was assessed by concordance, reproducibility and
consistency with Mendelian inheritance. SNPs with HapMap refer-
ence calls in the individuals genotypedwere assessed for concordance
between array-derived and reference genotypes, with a minimum
concordance threshold set at 96% and a minimum call rate threshold
of 96%. For SNPs without HapMap reference genotype data, a
minimum threshold for the call rate of 98% was imposed. Reproduc-
ibility was calculated for each SNP as the fraction of genotype calls
concordant to the consensus call for all replicates of each sample. The
threshold for reproducibility was 97%. Mendelian inheritance consis-
tency was calculated as the fraction of offspring genotype calls in
keeping with parental genotypes. The threshold for Mendelian
inheritance consistency was 98.5%.
4.2. SNP selection for inclusion on the array
Two considerations guided SNP selection. First, we wished to
maximize the number of SNPs on the array. More SNPs allow for
greater genomic coverage. The array accommodates a ﬁxed total of
1.38 million features. The majority of SNPs require two features.
Limiting SNP selection to two-feature sets would, in theory, provideroom for 690,000 SNPs. However, because certain SNPs were deemed
as high priority (as described below), exceptions were made to allow
for higher multiple-feature and multiple-probe SNPs. In addition,
some high-value SNPs were tiled on the array in multiple replicates to
improve the chances for high quality genotype calls.
The second consideration is that not all SNPs are equal in
importance. SNPs based on strongly conﬁrmed trait or disease
associations are of highest value, while SNPs chosen for genomic
coverage may have no particular signiﬁcance beyond their ability to
predict genotypes of other SNPs. We therefore divided SNPs into
selection tiers based on a hierarchy of importance. Some SNPs were
included because of known function or disease/trait association; some
SNPs were selected to “cover” or “tag” SNPs of known importance
which could not be converted in the Axiom assay, or for which we
desired redundant coverage; and ﬁnally others were selected
algorithmically to optimize the coverage of general genetic variation
across the entire genome. SNP selection proceeded progressively
down tiers of importance, as described below.
4.2.1. Stage 1: A preselected set of SNPs
We ﬁrst created a list of “preselected” SNPs of varying levels of
importance for inclusion on the array, deﬁned as primary, secondary,
tertiary, and gene enrichment, in decreasing level of signiﬁcance.
Because sources for these various tiers of SNPs often produced the
same SNPs, we assigned each SNP uniquely to its highest tier. Some of
these SNPs met QC standards of inclusion (and were directly tiled),
while others did not. For those that did not, we algorithmically
included neighboring SNPs to infer these high priority SNPs, as
described below. For some of the highest priority SNPs, we also
algorithmically included redundant coverage if possible.
There were 241 Primary SNPs. These were SNPs of highest
importance, based on strongly conﬁrmed trait or disease associations
derived from the literature and other database sources, such as the
NHGRI GWAS database [28] and the Human Genome Epidemiology
(HuGE) Navigator [29].
The secondary group consisted of 7929 SNPs that were obtained
from various literature and public database sources as suggestive of
associationwith adiseaseor trait, butnot yet as strongly replicated. Each
SNP in the secondary set was included on the array if it produced high
quality genotypes on the Axiom platform. The SNPs in this secondary
group were identiﬁed from a variety of sources, including: Pharmaco-
genetics Knowledge Base (PharmGKB) [30] and Pharmacogenetics of
Membrane Transporter (PMT) database [31] for SNPs of pharmacoge-
netic interest; Candidate SNPs compiled from the literature; NHGRI
GWAS database for SNPs with association P-valuesb1e−5 (appearing
in the literature as of January, 2010); HuGE Navigator database for the
most-cited candidate gene association SNPs.
The 72,324 tertiary SNPs weremined from various database sources
and were based on potential functional signiﬁcance. The list of sources
for these SNPs included miRNA SNPs; splice site SNPs; MHC (chromo-
some 6p) SNPs; coding synonymous and non-synonymous SNPs; other
SNPs preselected for high value from the Affymetrix commercial CEU
array; and KGLP SNPs in functionally important regions.
At a similar level of importance to the tertiary set was the gene
enrichment set deﬁned as 198,771 SNPs chosen from exonic and
ﬂanking regions of genes. The ﬂanking regions included 10Kb
upstream of the ﬁrst exon, 10Kb downstream of the last exon, and
±50 bp ﬂanking regions for all intermediate exons for 4246 genes
that were conﬁrmed or suggestive of potential disease or trait
associations. The gene sources for these SNPs included the HuGE
database (most often cited genes), genes of neuro-endocrine interest,
HLA genes, telomere genes, genes of pharmacogenetic interest, genes
of environmental interest identiﬁed from the NIEHS website, and
genes identiﬁed in GWAS studies from the NHGRI database.
To screen out variants that are not polymorphic in Europeans and
false positives in the tertiary and gene-enrichment sets, we required
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individuals in a database generated by Affymetrix during their SNP
screening for the Axiom platform. For the tertiary set, this resulted in a
total of 59,063 SNPs for inclusion. For the gene-enrichment set, this
resulted in a total of 107,706 SNPs.
The number of validated primary, secondary and tertiary SNPs that
were directly tiled on the array was 153, 4,094 and 48,252,
respectively. Our strict validation criteria were previously outlined.
A few very high priority SNPs that were not validated were also tiled
on the array, to allow for the possibility that they would still provide
useable genotype data. We did not directly tile all the validated gene
enrichment SNPs, but rather included them in the ﬁrst target set for
greedy algorithm SNP coverage as described below.
4.2.2. Stage 2: Additional coverage of preselected SNPs
To insure successful inference of the primary SNPs, layers of
additional high QC SNPs were added. First, a single 'tagging' SNP in
sufﬁciently high LD (r2N0.6) was included, when available. Subse-
quently, we greedily constructed a multiple marker “imputation tag”
(r2 calculation details described in the genome-wide coverage section
below) from a 100 kb window around each primary SNP, both those
that could not be directly tiled and those that could, adding respective
coverage and redundant coverage. SNPs increasing r2 bymore than 3%
were continuously added, prioritizing SNPs with better performance
ﬁrst, until no further SNPs could be added.
For secondary SNPs that could not be directly tiled, we assigned a
single tagging SNP (with r2N0.6), if available. If no tagging SNP was
available, imputations were performed and the most predictive SNPs
were added as described above for primary SNPs.
No tagging or imputation SNPswere added for the tertiary or gene-
enrichment SNPs. However, additional coverage was provided as the
ﬁrst step of the whole genome coverage stage as described below.
4.2.3. Stage 3: Redundant and genomewide coverage
SNPs selected for genome-wide coverage were obtained from
several database resources, including HapMap, dbSNP, and the KGP.
Genotypes from the HapMap database were included in the coverage
analysis for SNP selection. Genotypes of SNPs identiﬁed by the KGP or
in dbSNP, but not HapMap, were determined by screening on the
Axiom™ platform in the HapMap2 CEU, CHB, JPT, and YRI populations
(previous work by Affymetrix, results not shown).
An incremental greedy heuristic was used in the genome-wide
coverage rounds, in which SNPs were chosen for their ability to cover
one or more set of target SNPs according to multiple competing
criteria. As with the preselected set, the most important coverage goal
was pursued in the ﬁrst selection round, followed by a descending
sequence of less important goals in subsequent selection rounds.
The need to optimize across multiple criteria led to several rounds
of coverage optimization. Within each round, SNPs were chosen from
a set of candidate SNPs one at a time. Selection was based on multiple
criteria, including: the marginal increase in coverage of the Caucasian
population gained from inclusion of the candidate SNP; the observed
robustness and accuracy of the assay for the candidate SNP; and the
absence of nearby SNPs within the 30-mer probe sequence. These
optimality criteria were set forth in a selection process, which
reﬂected the hierarchical set of optimization priorities. At each level
a conﬁgurable range of optimization measures were considered to be
a tie, so that, e.g., a SNP would not necessarily be selected only for
providing negligibly greater marginal coverage than a more robust
alternative. If a single SNP was optimal for the criterion under
consideration, with no others close enough to be tied, it was chosen.
Otherwise, the subset of SNPs that were tied was tested in the same
manner against the next criterion level, until a unique optimal SNP
was identiﬁed. If no optimal SNP could be chosen, one was randomly
selected from the remaining candidates. By controlling the size of theregion of optimization measures that was considered a tie, we could
investigate tradeoffs among multiple criteria.
A guiding principal for SNP selection was the concept of a “target
set” (SNPs to be included or covered by LD on the array), a “selected”
set (SNPs chosen to be included on the array), and a “candidate” set
(SNPs that passed our validation criteria for inclusion, as previously
deﬁned). The ﬁrst step was to include the preselected set of SNPs
described above under Stage 1 in the “selected” set. The second step
was to include SNPs chosen to provide coverage or redundant
coverage of the preselected set in the “selected” set. The next round
of SNP selection was used to maximize the coverage across the whole
genome. Here, a SNP was considered covered if it was 'tagged' by at
least one selected SNPwith r2 greater than 0.8. This round contributed
the bulk of the array's SNPs. A ﬁnal round again maximized genomic
coverage, but allowed coverage with a lower r2 threshold of 0.6 to
capture SNPs that could not be covered at high correlation. Fig. 7 shows
a summary of the coverage algorithm in the form of a ﬂow chart.
4.2.4. Deﬁnition of the target set
The target set for the ﬁrst round of greedy tag SNP selection
(166,769 SNPs) consisted of SNPs with LD data and with MAF≥0.01
from the tertiary and the gene enrichment set of SNPs In this round,
32,066 additional SNPs were moved from the “candidate set” to the
“selected set.” The second round of greedy tag SNP selection was
carried out for redundant coverage for the primary, secondary,
tertiary and gene enrichment SNPs. SNPs with LD data and with
MAF≥0.01 from all four categories of SNPswere included in the target
set (173,549 SNPs). A total of 37,776 SNPs were moved from the
“candidate set” to the “selected set” in this round. For the next round
of greedy tag SNP selection all SNPs in the genome with LD data and
with MAF≥0.02 were included in the target set (3,505,510 SNPs),
excluding SNPs already in the “selected” set. In this round, 544, 607
SNPs were added. The ﬁnal round of greedy tag SNP selection used the
same target set for genome-wide coverage with SNPs in or covered by
the “selected” set removed from the target set; for this round, a lower
threshold of r2=0.6 was used, and 9,294 SNPs were added. For all
target sets, SNPs with only one homozygous genotype for the minor
allele and no heterozygous genotypes in CEU samples were excluded.
4.3. Quality assessment for samples run on the ﬁnal microarray product
The primary chip-level quality metric for Axiom™ microarrays is
“DQC,” a measure of interference between the channel-to-channel
signal contrast distributions of probes that complement genomic
sequence with no expected polymorphism, half of which have
foreground signal in one channel and half in the other. The DQC value
is highly correlated with sample call rate. Loss of this correlation
indicates sample or assay problems such as contamination or mixing of
DNA, or technical issues with hybridization. Low DQC values likewise
indicate problems such as low input DNAmass. DQC ranges from 0 to 1;
we employed a minimum threshold of 0.82 for further analysis of a
sample; samples with low DQC were not included in genotyping
analysis. Subsequently, for a genotyped sample, the call rate was
determined across all SNPs for an individual. A minimum threshold of
97%was employed to declare that a samplewas successfully genotyped.
After removal of failed samples, re-genotypingwas performed to obtain
more accurate genotypes for the remaining samples.
4.4. Quality assessment of SNPs on the ﬁnal microarray product
SNP performancewas assessed in the experimental work primarily
on the basis of call rate and reproducibility of genotype calls in
replicated samples. As described below, a single duplicate sample was
included on each plate for QC purposes. Reproducibility of genotypes
was then calculated based on these duplicates.
No
Yes
Can we 
cover more  
target SNPs 
using 
available 
SNPs?
Stop
Choose all available  SNPs that contribute 
maximally to coverage, within a narrow range
Of those, choose most robust SNPs  
Of those, choose SNPs with best QC score
…
If more than one candidate remains, randomly 
choose a single one
Update selected SNP list with new addition
Start SNP Selection R
ules
Target SNPs to cover  
by selection or  
tagging
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selected SNPs: biologically 
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rounds)
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(validated & available 
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Fig. 7. Greedy SNP selection algorithm. A set of SNPs are chosen for reasons of biological importance, signiﬁcance in published GWAS, etc., or as the result of previous rounds of
greedy SNP selection. The “target” set of SNPs to be covered by tagging is established to ﬁt the purpose of the current round of SNP selection, e.g., maximize coverage of SNPs in coding
regions, or maximize general coverage of the genome. Then, SNPs which are available to be placed on the microarray are assessed for their ability to increase coverage of the target
set. If coverage can be increased, a set of decision rules is applied to select the best single SNP to add to the selected list, as described in the text. This process continues until maximum
coverage of the target set is achieved, or no space for additional SNPs on the microarray remains.
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Environment and Health (RPGEH) Genetic Epidemiology Research in
Adult Health and Aging (GERA) cohort
The Axiomarray developmentwe describe here derives fromanNIH
funded RC2 program entitled “A Resource for Genetic Epidemiology
Research in Adult Health and Aging.” As part of this program, wewill be
performing GWAS genotyping on 100,000 members of the Kaiser
Permanente Northern California (KPNC) membership who volunteered
for the Research Program on Genes, Environment and Health (RPGEH).
Participants provided a saliva sample in a whole-saliva collection kit
(Oragene™ DNA collection kit, DNA Genotek, Inc., Ottawa, Ontario,
Canada), from which DNA was extracted and normalized. Participants
provided broad written informed consent for use of their DNA and
resulting genetic data in health studies. The study received approval
from the KPNC Institutional Review Board. This is amulti-ethnic cohort,
including substantial numbers of Caucasians, African Americans, Asians
and Latinos. Tomaximize genomic coverage for low frequency variation
in each of these ethnic groups, we are creating four ethnic-speciﬁc
arrays, one for each of the above mentioned ethnic groups. We are
taking advantage of the high density customization enabled by the
Axiom platform. In this ﬁrst publication, we describe the array
developed for European Americans. To characterize the performance
of the newly developed array, we perform QC analysis on the ﬁrst 838plates, including ~80,000 participants of European ancestry from this
cohort.
As part of the experimental design for this project, we have
included duplicate samples on each plate. The plate contains space for
96 separate samples, one of which was a duplicate sample that was
included on a previously processed plate. In each case, we randomly
selected a sample that had been successfully genotyped on a prior
plate as a duplicate for the current plate. The analysis of reproduc-
ibility is based on a total of 818 duplicates.
4.6. Calculating genome-wide coverage for the ﬁnal microarray product
To assess the coverage performance of our array, we estimated the
correlation between each marker in a “target” set to the markers on
our array. In a GWAS analysis, typically SNPs not on the array will be
imputed from SNPs that are on the array, when possible. Therefore,
rather than using the maximum pairwise correlation within a ﬁxed
window around the SNP [12], we used imputation with regional
markers. Normally, one would use the same set of individuals for the
reference and predicted sets of genotypes in this analysis. However,
leaving the same individual in both sets leads to overﬁtting, and hence
overestimation of coverage. Therefore, we employed “leave-one-out
cross validation” to compute an unbiasedmultiple-marker estimate of
the correlation [32], as follows. For each individual in the predicted
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individuals to impute his (her) genotype via the software package
Beagle v3.3.0 [33]. In this fashion, the imputed value was not
inﬂuenced by an individual's actual genotype value. For each marker
and individual, we used the imputed probabilities of each genotype to
compute the expected value of the genotype under an additive coding
(i.e., E(X)=pAa+2pAA). Then, using all individuals in the predicted
set, the squared correlation r2 was calculated between the actual
additive genotype value and the expected value from the imputed
genotypes. For each SNP in the “target” set, the calculated r2
represents its coverage by SNPs present on the array. Finally, we
computed the coverage of the full “target set” by the array for a given
r2 threshold T as the proportion of the markers in the “target” set with
r2NT. One thing to note is that imputation performance can be
affected by the size of the reference panel (especially for lower minor
allele frequencies); therefore, to facilitate comparability between
coverage estimates on different sets of reference genotype data, we
used 59 or 60 independent CEU HapMap individuals. For most
analyses, these were the CEU founders, but in a few analyses it
included a child instead of parents.
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